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Tesis por compendio de publicaciones 
En el actual contexto universitario, la calidad de la formación así como de los 
resultados de la misma tiene un papel relevante. Teniendo en cuenta que una de las 
competencias básicas que debe adquirir el doctorando es la capacidad de comunicación 
con la comunidad académica y científica, las publicaciones en revistas especializadas 
garantizan la adquisición de esta competencia, además de otras relacionadas con ella. 
Por ello, y con el consentimiento de mi director, he creído conveniente que la 
Tesis Doctoral que aquí se presenta tenga este formato por las siguientes razones: a) 
porque permite comunicar a la comunidad científica los resultados obtenidos de una 
forma rápida, no teniendo que esperar varios años hasta la finalización del proyecto de 
tesis, lo cual puede provocar que los hallazgos pierdan originalidad e interés; b) porque 
uno de los principales criterios por los que se mide la calidad de un trabajo científico es 
a través del nivel de impacto de las revistas en las que éste es publicado. El conjunto de 
trabajos presentados en esta Tesis, y que he realizado con la ayuda de mi director y 
otros compañeros, se ha publicado en revistas internacionales con impacto, tras estrictas 
revisiones llevadas a cabo por expertos en el área de la Hepatología, lo cual creemos 
que es motivo de satisfacción, puesto que se trata de un importante indicador de la 
calidad del trabajo realizado. 
Los miembros del tribunal comprobarán que los trabajos publicados están 
firmados por varios autores. Este hecho se debe a que dichos trabajos han sido 
realizados en colaboración con otros compañeros de distintos departamentos, sin los 
cuales la tarea habría sido difícilmente abordable.  
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Abbreviations 
BT: Bacterial translocation. 
CFF: Critical flicker frequency. 
COX: Cyclooxigenase. 
CT: Computerized tomography. 
DM: Diabetes mellitus. 
EEG: Electroencephalography. 
HCV: Hepatitis C virus. 
HE: Hepatic encephalopathy. 
HR: Hazard ratio. 
ICT: Inhibitory control test. 
IGF: Insulin like growth factor. 
IL: Interleukin. 
IRS: Insulin receptor substrate. 
MHE: Minimal hepatic encephalopathy. 
MRI: Magnetic resonance imaging. 
NAFLD: non-alcoholic fatty liver disease. 
NASH: non-alcoholic steatohepatitis. 
OR: Odds ratio. 
PHES: Psychometric hepatic encephalopathy score. 
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PPAR: Peroxisome proliferator-activated receptor. 
RBANS: Repeatable Battery for the Assessment of Neurological Status. 
RR: Relative risk. 
SIBO: Small intestinal bacterial overgrowth. 
TIPS: Transjugular intrahepatic porto-systemic shunt. 
TNF: Tumor necrosis factor.  
TZD: Thiazolidinediones.  
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Introduction 
Liver cirrhosis 
ETIOLOGY AND EPIDEMIOLOGY 
Liver fibrosis is the excessive accumulation of extracellular matrix in response 
to acute or chronic liver injury. Liver cirrhosis is the final stage of liver fibrosis, 
characterized by the histological development of regeneration nodules surrounded by 
fibrous tissue, and leading to a loss of normal liver function and appearing metabolic 
and hemodynamic disturbances
[1]
. The main causes of cirrhosis are alcoholic liver 
disease, hepatitis C (HCV), hepatitis B, non-alcoholic steatohepatitis (NASH), 
autoimmune hepatitis and primary biliary cirrhosis
[2]
. Interestingly, the etiology of 
cirrhosis differs across the world. Viral hepatitis is the leading cause of cirrhosis in 
developing countries and alcoholic liver disease, HCV and NASH are the most 
significant causes of cirrhosis in the developed countries
[3]
.  
In many developed countries, the death rates from liver cirrhosis have been 
declining in the recent years; especially those derived from alcohol-related cirrhosis. By 
contrast, an increase has been observed in a few Eastern European countries and 
England
[4]
. In United States, there has been an increase by HCV compared to alcoholic 
liver disease. Data about patients’ characteristics at diagnosis show that the mean age is 
around 60 years, being more frequently in male sex. The highest mortality from liver 
cirrhosis is in the age group 60-70 years
[5]
. 
DIAGNOSTIC METHODS 
The diagnosis of cirrhosis is based on a combination of clinical, ultrasound, 
biochemical and histological findings (Table 1). Liver biopsy is still considered the 
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“gold standard” for the diagnosis of cirrhosis, but is being less employed over time. A 
liver biopsy shows some procedural risks, including bleeding, considerable discomfort 
for the patient and even a risk of death
[6]
. Consequently, several other non-invasive 
methods for diagnosis are being more commonly employed and evaluated. These 
include transient elastography, magnetic resonance elastography and combinations of 
ultrasound, computerized tomography (CT) and magnetic resonance imaging (MRI). In 
addition, combinations of tests and a number of non-invasive models for predicting liver 
fibrosis have been developed
[7]
. 
Imaging modalities 
Ultrasonography 
CT/MRI 
Transient elastography 
Acoustic radiation force impulse imaging 
MR elastography 
Indirect serum non-invasive fibrosis 
tests 
APRI 
FIB-4 
Forns index 
Proprietary serum non-invasive fibrosis 
tests 
Fibrotest 
ELF 
Hepascore 
Fibrometer 
 
Table 1. Diagnostic methods for liver cirrhosis. 
 
CLINICAL RELEVANCE 
Cirrhosis affects hundreds of millions of patients worldwide. It is the final stage 
of liver fibrosis as a result of the disorganization of the connective tissue and the 
regeneration of hepatic parenchymal cells
[8]
. In the evolution of many chronic liver 
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diseases, cirrhosis is a stage that has been considered irreversible although the evidence 
that fibrosis and even cirrhosis can be reversible is growing
[9]
. The chronic liver disease 
promotes an underlying immunological response which causes persistent inflammation 
and tissue repairing and, ultimately, leads to fibrosis and cirrhosis. This latter can be 
stabilized controlling the primary disease (e.g. antiviral therapy, immunosuppressive 
therapy, exercise). However, the presence of liver cirrhosis can involve an increased 
risk of developing portal hypertension and intrahepatic shunting of blood, together with 
impaired protein synthesis and hormone metabolism
[10]
. Therefore, clinical 
manifestations of cirrhosis range from asymptomatic to symptomatic depending on the 
nature and the severity of the underlying liver disease. Over time, liver cirrhosis is 
associated with severe complications which lead to decompensate cirrhosis from 
compensated cirrhosis
[11]
. These are variceal bleeding, ascites, hepatic encephalopathy, 
hepatorenal syndrome, bacterial infections such as spontaneous bacterial peritonitis and 
hepatocellular carcinoma. Patients suffering such complications show 50% of 5-year 
mortality.  
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Hepatic encephalopathy 
INTRODUCTION 
Hepatic encephalopathy (HE) is one of the major complications of liver 
cirrhosis, affecting up to one third of cirrhotic patients. HE can be defined as a complex 
neuropsychiatric disturbance that occurs in patients with liver dysfunction. It ranges 
from minimal behavioral abnormalities to deep coma. The clinical prognosis is poor 
after HE has developed, with 1-year survival estimated at 42% and 3-year survival at 
23%
[12]
. HE is classified in three types: type A, associated with acute liver failure; type 
B, related to porto-systemic shunting without intrinsic liver disease; and type C, linked 
to cirrhosis
[13] 
(Table 2). Of all these types, HE associated with liver cirrhosis is the 
most prevalent. It is often the result of hepatic parenchymal damage or increased porto-
systemic shunting. However, one or more precipitating factor can be identified in about 
60%-70% of cases
[14]
. HE in cirrhosis can be treated satisfactory, either by non-
absorbable disaccharides or antibiotics, or by eliminating the precipitating factors. 
Ultimately, liver transplantation is available as the last option in those cirrhotic patients 
with liver insufficiency and recurrent episodes of HE
[15]
. However, we can identify two 
major groups of cirrhotic patients with an increased risk of chronic recurrent episodes of 
HE, and which cannot be satisfactory treated with the current treatment. Firstly, patients 
showing contraindications for liver transplantation (i.e. old cirrhotic patients, patients 
treated with a transjugular intrahepatic porto-systemic shunt (TIPS)). Secondly, 30%-
50% of cirrhotic patients show minimal hepatic encephalopathy (MHE)
[16]
. This entity 
represents the first stage in HE spectrum (Figure 1). MHE is defined as the presence of 
cognitive abnormalities in patients with liver disease, which are not detected with 
common examinations; it is diagnosed using sensitive neuropsychological and 
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neurophysiological tests
[17]
. It is characterized, additionally to cognitive impairment, by 
decreased attention, poor concentration, impaired memory, sleep disturbances and 
psychomotor slowing. Furthermore, MHE predicts the appearance of HE and survival in 
cirrhotic patients
[18]
, as well as increases the risk of having a car accident
[19]
 and falls
[20]
. 
 
Type Definition 
A  Acute and hyperacute liver failure  
B  Portosystemic bypass without intrinsic hepatocellular disease  
C  Cirrhosis and portal hypertension with portosystemic shunts  
 
Table 2. Classification of hepatic encephalopathy. 
 
 
 
 
 
 
 
 
Figure 1. Spectrum of hepatic encephalopathy. 
 
PATHOGENESIS 
The pathophysiology of HE is multifactorial and complex, and it remains poorly 
understood. Traditionally, hyperammonemia has been considered the cornerstone of 
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HE. However, over the past decade, coexisting factors have emerged, such as the 
systemic inflammatory response or the presence of genetic factors, which seem to have 
a synergistic role in pathophysiology of HE (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Potential hyperammoniagenic conditions. 
 
Role of the ammonia 
Ammonia is a normal physiologic product of intermediary metabolism, 
compound of nitrogen and hydrogen (Figure 3). The human body has several sources of 
ammonia. It is produced, mainly, after glutamine deamidation by glutaminase in small 
intestine (particularly in duodenum), as well as the urea hydrolyzed by gut bacteria
[21]
. 
Three glutaminase isoforms have been described: kidney type glutaminase, which is 
expressed in many mammalian tissues; liver type glutaminase, which was originally 
identified in hepatocytes; and type C present in peripheral mononuclear cells
[22]
. The 
17 
 
intestinal activity of glutaminase has been found to be higher in cirrhotic patients than 
in healthy controls
[23]
.  
 
 
 
 
 
 
 
 
 
Figure 5. Ammonia detoxification: glutamine cycling and ureagenesis. 
 
Ammonia is toxic at elevated concentrations and must be removed from the 
body (Figure 4). In fact, ammoniagenic conditions (ingestion of a protein load, 
constipation or a gastrointestinal bleeding) often result in HE, because of an elevation of 
ammonia concentration in the brain. Normally, the hepatic metabolism of ammonia 
takes place in two parts: a) the periportal hepatocyte, through the urea cycle (the most 
important step); b) near the central vein, hepatocytes transform the rest of ammonia into 
glutamine
[24]
. In cirrhosis or in presence of portosystemic shunts, the ammonia 
detoxification takes place in muscle, through glutamine synthesis (by glutamine 
synthetase). A hypoproteic diet decreases both muscle mass and ammonia 
detoxification. Thus, muscle and, consequently nutritional status, play an essential role 
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in cirrhotic patients
[25] 
(Table 3). On the other hand, the kidney is an organ capable of 
synthesizing and degrading ammonia. In liver disease, 70% of the synthesized ammonia 
is excreted in the urine, while decreases up to 30% of the ammonia under normal 
conditions
[26]
. Therefore, a renal failure may aggravate the cognitive status during HE. 
 
 Glutaminase  Glutamina-synthetase  
Low protein  --  --  
High protein  ++  =  
Starvation  ++  -  
Diabetes mellitus  ++++  +  
 
Table 3. Regulation of hepatic glutaminasa and glutamine synthetase. 
 
 
 
 
 
 
 
 
 
Figure 4. Pleomorphic effects of ammonia. 
 
On the other hand, astrocytes are the only cells which metabolize ammonia in 
the brain. As muscles, they have glutamine synthetase and are able to convert glutamate 
and ammonia in glutamine, moving water into the astrocyte (glutamine is an 
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osmocyte)
[27]
. As a result, the astrocytes swell, and this process leads to cerebral edema 
and intracranial hypertension
[28] 
(Figure 5). However, this situation is more usual in 
acute liver failure than in chronic liver failure
[29]
. After a long exposition to ammonia, 
astrocytes change their morphology into Alzheimer’s type II astrocytes[30], whose 
number correlates with the encephalopathy intensity
[31]
. This situation (brain edema) is 
compensated by the releasing of some osmolytes, such as myoinositol and taurine 
(homeostatic mechanism)
[32]
. On the other hand, hyperammonemia also produces 
reactive oxygen species in the central nervous system. Reactive oxygen species induces 
astrocyte swelling and mobilization of Zn, which mediates mRNA expression of 
metallothionein and the peripheral benzodiazepine receptor
[33]
. Resting of membrane 
potential or suppression of inhibitory postsynaptic potential formation are other effects 
of ammonia on the neural cells
[34]
. 
 
 
 
 
 
 
 
Figure 5. Mechanisms and effects of ammonia uptake into the brain. 
 
Systemic inflammatory response 
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Systemic inflammation is common in liver failure and its acquisition is a 
predictor of hepatic encephalopathy severity
[35]
. An efficient recognition of systemic 
inflammation may change the natural history of HE and contribute to reduce circulating 
endotoxemia and immune cell dysfunction by developing novel therapeutic strategies. 
Neuroinflammation 
Pathophysiological mechanisms of HE are closely related to changes on the 
blood-brain barrier (made of endothelial cells and astrocytes), a highly specialized 
separation of brain microvasculature
[36]
. It is essential for the proper function of the 
central nervous system; among others, protects the brain from many common bacterial 
infections or toxins and from fluctuations in the blood plasma components. During 
infection, microglia cells (the resident macrophages of the brain) are activated and 
astrocytes release pro-inflammatory cytokines (tumor necrosis factor (TNF) α, 
interleukin (IL)-6), which enhance neuropsychological impairments induced by 
hyperammonemia
[37]
. Shawcross et al. reported the impact of systemic inflammatory 
response on ammonia-induced brain dysfunction in cirrhotic patients
[38]
. Several studies 
have documented that TNFα levels are higher in cirrhotic patients than in healthy 
subjects, with a positive correlation between them and HE severity
[39]
. Normally, the 
blood-brain barrier remains intact, preventing the entry of cytokines into the brain. 
However, pro-inflammatory cytokines (e.g. TNFα and IL-1) may produce brain 
swelling by inducing an increase in the permeability of the blood brain barrier
[40]
. In 
fact, treatment based on a TNF receptor antagonist (etanercept) reduces the severity of 
HE and prevents brain edema
[41]
. Treatment with infliximab, another monoclonal 
antibody against TNF, has also been shown to delay the progression of HE in rats
[42]
. 
Similarly, serum levels of IL-6 are correlated with the presence of MHE and its 
severity
[43]
, as well as the cognitive function
[44]
. Precipitating factors for HE, such as 
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sepsis, hyponatraemia, gastrointestinal haemorrhage and renal failure, are known to 
increase production of TNFα[45]. Moreover, the therapeutic effect of hypothermia and 
non-steroidal anti-inflammatory drugs has been found to protect from central pro-
inflammatory processes in mild HE, reducing the activation of microglial cells, which 
supports the concept of neuroinflammation
[46]
. Indeed, cyclooxygenase inhibitors, 
which were investigated in fulminant hepatic failure in a rat model, have shown that 
cyclooxygenase-1 rather than cyclooxygenase-2, plays a major role in HE, due to 
decreases the mortality and improves motor activities
[47]
.  
Bacterial translocation 
Bacterial infections are well-known triggers for HE in patients with cirrhosis
[48]
. 
They are frequent complications in patients with cirrhosis (80% are caused by Gram-
negative bacilli). Bacteria go through the gastrointestinal tract to extraintestinal sites, 
such as the mesenteric lymph node complex, liver, spleen, kidney and bloodstream, 
developing spontaneous bacterial peritonitis or bacteraemia
[49]
 (Figure 6). Bacterial 
translocation (BT) may be caused by viable bacteria, as well as by fragments 
(endotoxins) or bacterial DNA. The following factors have been implicated in the 
appearance of BT: impaired immunity, small intestinal bacterial overgrowth (SIBO) and 
increased intestinal permeability
[50]
. Therefore, inflammatory response (derived from 
BT) may have a role in the pathogenic mechanisms involved in HE, due to circulating 
endotoxins produce TNFα and others cytotoxic molecules by activating 
macrophages
[51]
. Moreover, Jung et al. observed a very high frequency of SIBO in 
cirrhotic patients, showing a high correlation with BT and suggesting that SIBO could 
be a major risk factor of BT
[52]
. Hung et al. concluded that infections increase the 
mortality by HE in cirrhotic patients, especially pneumonia and sepsis without specific 
focus, after analyzing 4,150 adult cirrhotic patients hospitalized
[53]
. Recently, these 
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findings have been confirmed by Merli et al., who have documented a cognitive 
impairment (overt or subclinical) in 42% of cirrhotic patients without infection, in 79% 
with infection without SIRS and in 90% with sepsis
[54]
. Therefore, we should be 
cautious with bacterial infections in cirrhotic patients. 
 
 
 
 
 
 
 
 
Figure 6. Mechanisms of bacterial translocation from gastrointestinal tract. 
 
Genetic factors 
Over time, genetic factors have been growing in importance in several fields. 
Data support the existence of genetic factors influencing the development of overt HE, 
due to cirrhotic patients showing the same degree of liver dysfunction (and suffering 
from the same trigger) may, or may not, develop overt HE
[55]
. Recently, Gorg et al. have 
carried out the first analysis of expression profiles of the whole transcriptome in post 
mortem cerebral cortex samples of cirrhotic patients with or without HE in comparison 
with patients without liver or neurological disease. The study showed a total of 638 or 
396 altered genes in patients with cirrhosis with or without HE, respectively, compared 
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with controls without cirrhosis. They observed increased mRNA expression levels of 
HO-1, as well as other mRNA species involved in anti-oxidative defense 
(peroxiredoxin-4, selenoprotein-V, and PPAR) but also in glucose metabolism, in 
patients with cirrhosis and HE but not in those without HE. Thus, these findings 
indicate that gene expression profiles can discriminate cirrhotic patients with HE from 
those without HE and support the role of impaired insulin signaling and oxidative stress 
in the pathogenesis of this entity
[56]
. The genotype B1B1 of the TNFβ gene has been 
reported underexpressed in patients with HE after acetaminophen intoxication
[57]
, but 
has not been confirmed in further studies. A polymorphism in the promoter region of 
the CD14 gene (-159C/T) was associated with HE, due to a strong relationship with 
advanced liver disease and systemic inflammation
[58]
. Nevertheless, all these association 
require confirmation in further studies.  
The human glutaminase gene (OMIM: 138280) is located on chromosome 2 
(2q32-q34). The full-length gene includes 84,675 basepairs and the glutaminase mRNA 
has 4784 basepairs (GenBank NM_014905)
[59] 
(Figure 7). In a prospective study (109 
patients with cirrhosis in the estimation cohort, 177 patients in the validation cohort, and 
107 healthy controls), Romero-Gomez et al. identified a microsatellite in the promoter 
region of the glutaminase gene (kidney type) to be between 8 to 29 fold repeat of GCA. 
The longest microsatellite correlated with higher glutaminase activity in vivo. It 
increased the risk for overt HE in cirrhotic patients from 20% to 40% (Hazard Ratio 
3.12 [CI: 1.39-7.02]; P=0.006)
[60]
. Furthermore, they carried out a functional analyses 
that showed how longer forms of the microsatellite promoted higher activity in vitro, 
which implied that it also promoted higher activity of the glutaminase gene, increasing 
number of glutaminase molecules and thus may enhance glutamine degradation and 
ammonia production
[61]
. Therefore, authors concluded that this factor was a genetically 
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determined difference in the conversion rate of glutamine to ammonia, explaining at 
least in part the variability in clinical presentation of HE. Mayer et al, confirmed these 
results in a cohort of 158 patients with liver cirrhosis, most of them in Child B/C. The 
long-long homozygous form (also called major homozygous) was independently 
associated with HE irrespective of age or TIPS
[62]
.   
 
 
 
 
 
Figure 7. Glutaminase gene is located in chromosome 2. 
 
MAIN DIAGNOSTIC TESTS 
In the process of HE, there are two levels of functional impairment which are 
essential to diagnose, depending on the stage in the HE spectrum: a) impairment in 
mental status; b) impairment in neuropsychological and neurophysiologic function.  
Clinical scales for overt HE 
Clinical diagnostic strategies for HE are defective because they are based on 
subjectivity. West Haven criteria are the most widely used clinical scale. It grades the 
patient’s mental state according to the behavior, intellectual function, alteration of 
consciousness and neuromuscular function, dividing patients from grade 0, which is 
normal, to grade 4, which is a coma
63
 (Table 4). However, results of this scale are not 
consistent and show poor reproducibility, similar to Glasgow scale (Table 5). 
25 
 
 
 Conscious Neuropsyquiatric symptoms Neurological symptoms 
Grade 0 
(MHE) 
Normal Impairments only detectable by 
psychometric tests 
None 
Grade 1 Slight mental 
impairment 
Dysphoria, irritability, anxiety Fine motor skills 
disturbed 
Grade 2 Fatigue, apathy, 
letarghy 
Subtle personality changes, slight 
disorientation, inappropriate 
behavior 
Flapping tremor, ataxia 
Grade 3 Somnolence to stupor Agression, gross disorientation Clonus, asterixis 
Grade 4 Coma None Signs of increased 
intracranial pressure 
 
Table 4. Stages of hepatic encephalopathy. 
 
GLASGOW  COMA SCALE   
Eye opening  Spontaneously  4  
 To speech  3  
 To pain  2  
 none  1  
Verbal response  orientated  5  
 confused  4  
 inappropiate  3  
 incomprehensible  2  
 none  1  
Motor response  Obeys commands  6  
 Localises to pain  5  
 Withdraw from pain  4  
 Flexion to pain  3  
 Extension to pain  2  
 none  1  
SCORE (max)   15  
 
Table 5. Glasgow scale. 
 
Neuropsychometric tests for MHE 
The psychometric HE score (PHES) is a group of neuropsychometric tests 
designed to diagnose the typical changes that characterize MHE in cirrhotic patients
64
. 
Germany, Italy, and Spain are the countries which have validated PHES for the 
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diagnosis of MHE
[65]
. It consists of the following tests: Number Connection Test-A 
(NCT-A), Number Connection Test-B (NCT-B), Line Drawing Test, Serial Dotting 
Test, and Digit Symbol Test (DST) (Figure 8). Depending on the standard derivation 
range in test results, patients receive points from 0 to -3. The cutoff which determines 
MHE is −4 points. There are others neuropsychometric tests, like the Repeatable 
Battery for the Assessment of Neurological Status (RBANS), although are less 
frequently used
[66]
. 
 
 
 
 
 
 
 
 
Figure 8. Psychometric hepatic encephalopathy score. 
 
Computerized psychometric tests for MHE 
Inhibitory control test (ICT) measures two different cognitive domains, response 
inhibition and attention, which are affected in patients with MHE
[67]
. ICT comprises of 
1728 stimuli, 40 lures and 212 targets. Worse psychometric performance is associated 
with a higher lure and lower target rate (a lure response above five indicates MHE with 
high sensitivity). Similarly, ICT also predicted the development of overt HE, changing 
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with the clinical status of the patients. Additionally to this, CDR is one of the tests 
created specifically for patients with MHE
[68]
. This test measures different mental 
aspects such as power and continuity of attention or quality of episodic and continuous 
memory. 
Neurophysiologic tests 
Critical flicker frequency (CFF) test was validated for the assessment of patients 
with HE in 2002
[69]
, although was devised originally as an ophthalmological test. The 
retinal glial cells, in patients with HE, undergo similar changes to those seen in cerebral 
glial cells, being this fact the basis of CFF. The device causes a stepwise decrease in 
frequency from 60 to 25 Hz. Main advantages are that the test results are not influenced 
by sex, occupation or education level, and are only slightly dependent on age. 
Furthermore, CFF under than 39 Hz diagnoses MHE with high sensitivity and 
specificity
[70]
. 
HE is associated with a decreased mean frequency of electrical activity in the 
brain, becoming electroencephalography in a good option
[71]
. The main problem is the 
needed to be performed under the supervision of a neurologist and require specialized 
equipment. Additionally, electroencephalography is able to detect the characteristic 
“triphasic waves” only in advanced HE, although in earlier stages 
electroencephalography analysis can predict the development of overt HE. 
Brain imaging 
Cerebral edema in patients with HE is detected by MRI. Many MRI techniques 
can identify low-grade cerebral edema. On the other hand, there are conditions which 
could simulate or exacerbate HE symptoms, such as subdural hematoma or a 
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cerebrovascular event. To prevent these cofounders, a CT scan of the head is a useful 
test
[72]
. 
CLINICAL RELEVANCE 
It is well-known that brain dysfunction adversely influences on the quality of life 
of patients and their performance. However, HE and especially MHE, are often 
neglected by hepatologists in clinical diary practice. Fortunately, the effect of these 
syndromes on daily activities is focusing the attention over recent years.  
The focus on the relationship between MHE and driving is more than justified, 
because vehicle accidents are associated with morbidity and mortality, as well as 
economic and social costs. Cirrhotic patients suffering HE are generally optimistic 
about their driving abilities. In fact, Kircheis et al. observed that 100% of patients with 
mild overt HE and 96% of those with MHE were convinced they were good drivers, 
significantly higher than control subjects (92%), concluding that HE patients 
overestimated their driving abilities
[73]
. However, the driving ability of patients with 
MHE is also reduced as several studies have demonstrated by simulated driving on 
virtual navigators and on-the-road driving. In fact, Bajaj et al. showed that treating 
MHE with lactulose is worth in order to prevent driving accidents, being the costs of 
screening and treating MHE reasonable according to the savings derived from the 
reduction in accident rates
[74]
. 
Cognitive dysfunction, such as HE, predisposes cirrhotic patients to fall as 
impairs attention and reaction capability
[75]
. The risk of fracture in cirrhotic patients is 
higher than general population, thus falls are particularly important in this population. 
This increased risk has several reasons: a) decreased bone mass due to malnutrition; b) 
hypogonadism; c) liver insufficiency
[76]
. Moreover, falls and traumas in cirrhotic 
patients have considerable complications and mortality. Cirrhotic patients with HE 
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showed an incidence of falls of 40.4%, in comparison with patients without HE who 
had an incidence of 6.2%, reaching a 52.3% the probability of falling after 1-year 
follow-up
[77]
. 
TREATMENT STRATEGY 
Many treatment options are available for patients with overt HE, while no 
evidence currently supports the treatment of MHE. In the management of overt HE, it is 
crucial to identify and correct the precipitating factors. It is common that most of 
patients show improvement in HE symptoms within 24–48 hours after the initiation of 
treatment (both empiric therapy and treatment of the underlying causes) (Figure 9). 
 
 
 
 
 
 
 
 
 
Figure 9. Relevant aspects of the treatment of hepatic encephalopathy. 
 
Non-absorbable disaccharides 
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Non-absorbable disaccharides (lactulose and lactitol) continue to be the main 
therapeutic options in the management of HE. In addition to having a laxative effect, 
lactulose and lactitol promote acidic stools and interfere with mucosal uptake of 
glutamine in the gut, consequently reducing the synthesis and absorption of 
ammonia
[78]
. 
Antibiotics 
Antibiotics have been found to be superior to non-absorbable disaccharides for 
the improvement of HE
[79]
. Antibiotics remove ammonia-producing bacterial flora and 
lower bacterial translocation and systemic inflammation. Rifaximin is a low-
gastrointestinal-absorption oral antibiotic with few adverse effects and the systemic 
drug interaction potential is low. A multicenter study demonstrated that the remission of 
HE was more prolonged in patients treated with rifaximin compared with those who did 
not receive it
[80]
. Neomycin was one of the first antibiotics to be investigated in the field 
of HE. The use of this antibiotic has declined over the past few years, due to adverse 
effects such as ototoxicity and nephrotoxicity
[81]
. 
Nutritional interventions 
Decreasing liver function and increasing porto-systemic shunting increases 
ammonia concentration, so in this situation skeletal muscle metabolizes ammonia in 
patients with chronic liver disease. However, cirrhotic patients usually show a loss of 
muscle mass due to typical the malnutrition status
[82]
. Consequently, the role of the 
muscle in detoxification of ammnonia is crucial. In fact, Cordoba et al. found that 
protein restriction did not improve the clinical evolution of acute HE
[83]
. Thus, a high-
protein diet in cirrhosis status is strongly recommended. The European Society for 
Parenteral and Enteral Nutrition recommends that cirrhotic patients should eat, at least, 
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1.2 g/kg of protein daily. They also recommend a diet supplementation with branched-
chain amino acids and vegetable protein once HE has developed
[84]
.  
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Diabetes mellitus 
EPIDEMIOLOGY AND CLASSIFICATION 
Diabetes mellitus (DM) is a chronic disease that usually appears in two 
situations: a) the pancreas does not produce enough insulin; b) insulin cannot be used 
effectively by the body. Accordingly, there are mainly two types of diabetes. On the one 
hand, type 1 diabetes mellitus (T1DM) is immune-mediated, requiring daily 
administration of insulin. On the other hand, type 2 diabetes mellitus (T2DM) is 
characterized by insulin resistance or relative insulin deficiency. T2DM is the most 
common form, involving 90% of people with diabetes around the world and the 
prevalence continues increasing (an increase of 20% is expected in developed countries 
in next ten years). Approximately, 285 million adults, aged 20-79 years, suffer from 
diabetes mellitus which corresponds to a prevalence of 6.4%
[85]
.  
T2DM results from an imbalance between insulin sensitivity and insulin 
secretion. The alteration of the capacity of the body to respond to insulin effects is the 
earliest detectable abnormality in the DM spectrum
[86]
. Consequently, the pancreas 
increases the insulin secretion to compensate impaired insulin action. During a period of 
time which varies depending on the individual susceptibility, compensatory 
hyperinsulinemia maintains glucose level within normal range but β-cells function 
eventually declines and leads to impaired glucose tolerance and overt diabetes 
mellitus
[87]
. 
INSULIN RESISTANCE 
Insulin resistance occurs at an early stage in the development of T2DM (Figure 
10). There seems to be a continuum from normal glucose tolerance to DM. Insulin 
resistance leads to increase insulin secretion by the pancreatic β-cell, achieving normal 
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glucose levels at the expense of elevated serum insulin levels. Ultimately, pancreatic β-
cells fail to compensate for the insulin resistance, leading to a condition known as 
impaired glucose tolerance. Over the years, pancreatic β-cells function deteriorates 
appearing T2DM. This fact is relevant as insulin resistance not only impairs glucose 
homeostasis, but is also associated with hypertension, dyslipidemia and abnormalities in 
coagulation and fibrinolysis. Insulin receptor substrate (IRS)-1 and IRS-2 appear to be 
the important mediators of insulin signalling in humans. IRS-1 is the first molecule 
downstream in the insulin-signalling cascade and is specifically involved in skeletal 
muscle and IRS-2 in adipose tissue insulin signalling. In the liver, impaired insulin 
signalling from IRS-1 to PKB/Akt leads to increased glucose production via inhibition 
of gluconeogenic enzymes. In addition, glycogen synthesis is inhibited and, at least in 
rodents, impaired IRS-2 signalling to aPKC leads to increased VLDL synthesis. 
 
 
 
 
 
 
 
Figure 10. Effects of insulin resistance. 
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INSULIN SENSITIZERS 
Metformin is an insulin-sensitizer drug frequently used in the first-line oral 
treatment of T2DM patients, belonging to biguanide class. It is generally well tolerated, 
and its role inducing weight loss has been postulated to be beneficial, as well as the 
decreasing of low-density-lipoprotein and triglycerides levels. Metformin works 
increasing beta oxidation of free fatty acids and reducing the hepatic gluconeogenesis 
via activation of 5’adenosine monophosphate-activated protein kinase (AMPK) 
pathway; decreasing intestinal glucose absorption; and increasing glucose uptake in 
skeletal muscle
[88]
. Furthermore, it is able to modulate the expression of pro-
inflammatory cytokines, such as TNFα and IL-6[89]. Recent studies indicate that 
metformin has antioxidant, anti-inflammatory, growth inhibitory and antiangiogenic 
effects, reducing the risk of some solid tumors, such as prostate, colorectal, breast and 
pancreas
[90]
. 
 Thiazolidinediones (TZD), especially pioglitazone, is another drug class of 
insulin sensitizers. TZDs act by activating PPARs (peroxisome proliferator-activated 
receptors), a group of nuclear receptors that regulates gene expression in liver, adipose, 
vascular endothelium and muscle tissue. They stimulate maturation of visceral fat, and 
hence change the adipocytokine profile secreted by adipose tissue. TZDs lead to an 
increase in adiponectin levels, which counteracts pro-inflammatory cytokines such as 
TNFα and promote beta oxidation of fatty acids via AMPK activation[91]. 
DIABETES AND LIVER DISEASES 
Hepatitis C 
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Core protein of hepatitis C virus plays a central role in the development of 
insulin resistance, by mechanisms which depend on viral genotype (particularly, in non-
3 genotype)
[92]
. It inhibits PPAR-γ expression and promotes degradation (by over-
expressed TNFα) of IRS-1 and IRS-2, which is balanced with an increase of glycaemia 
(decreasing glucogenogenesis and increasing gluconeogenesis and liver-related 
production of glucose)
[93]
. In fact, when viral clearance is obtained, the expression of 
IRS-1 and IRS-2 is restored and HOMA-IR index decreases, which indicates the 
independent role of HCV in insulin resistance
[94]
. Furthermore, there are other non-
structural proteins, like NS5A and NS5B, which also promote insulin resistance, 
enhancing TNFα and IL-6. Ultimately, the insulin resistance state favors the viral 
replication, promotes the fibrosis progression and has been associated with lower rates 
of rapid viral response, as well as sustained viral response
[95]
. 
Non-alcoholic fatty liver disease 
NAFLD is present when fatty infiltration affects >5% of hepatocytes, in the 
presence of <20g of alcohol consumption per day, without evidence of other causes of 
liver disease
[96]
. Pathophysiology of NAFLD is based in “two-hit hypothesis”, which 
consists in initial accumulation of steatosis in hepatocyte and a second hit, due to 
oxidative stress, for the development of necroinflammation
[97]
. Insulin resistance 
promotes fatty acid accumulation in the liver, resulting in increased β-oxidation and 
oxidative stress. Increased mitochondrial fat oxidation produces reactive oxygen species 
and upregulates the nuclear factor kappa-B, which activates the transcription of several 
pro-inflammatory genes and the production of pro-inflammatory cytokines (TNFα, IL-6 
and IL-8)
[98]
. Furthermore, insulin resistance increases leptin and decreases adiponectin 
levels. Finally, all these steps lead to NASH. 
Fibrosis progression and cirrhosis outcomes 
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In patients with chronic hepatitis C, studies have shown a significant relationship 
between the degree of steatosis and severity of fibrosis
[99]
. It has been suggested that 
insulin resistance may result from steatosis, as excess free fatty acids could 
downregulate IRS-1 signalling. Because of steatosis is associated with insulin 
resistance, fibrosis could be the result of hyperinsulinemia. In fact, it has been 
demonstrated that high levels of insulin and glucose could promote fibrogenesis by 
stimulating the release of connective tissue growth factor, a fibrogenic growth factor, 
from hepatic stellate cells
[100]
. 
The risk of spontaneous bacterial peritonitis and ascites is increased in subjects 
with DM. Sorrentino et al. compared 36 subjects with ascites due to cryptogenic 
cirrhosis with 108 healthy controls, concluding that ascites was related to different 
components of metabolic syndrome, such as diabetes mellitus
[101]
. In this pathology, 
there is an increased baseline inflammatory activity (via IL-6 and TNFα) and a 
decreased intestinal motility, which facilitate the bacterial translocation
[102]
. The role of 
pro-inflammatory cytokines could be similar in variceal bleeding, as Camma et al. 
demonstrated in 104 patients with hepatitis C
[103]
. Regarding to the association between 
insulin sensitizers and outcomes like spontaneous bacterial peritonitis, ascites and 
variceal bleeding, there are not studies published yet. 
Hepatocellular carcinoma 
Diabetes mellitus has been proposed as risk factor to develop HCC in recent 
studies. Wang et al. have documented in a meta-analysis an increased prevalence of 
HCC (RR 2.31), as well as mortality (RR 2.43) in subjects with diabetes mellitus
[104]
. 
Other studies demonstrated that survival after a HCC curative treatment, recurrence 
rate
[105]
 and macro-vascular invasion
[106]
 were more often seen in diabetics. 
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Furthermore, diabetes mellitus has been associated with the presence of metastatic 
disease among HCC patients
[107]
. 
It has been suggested that hyperinsulinemia, caused by insulin resistance, 
increased levels of insulin like growth factor-1 (IGF-1), which is one of the most potent 
activators of cellular proliferation via the Akt/mTOR signaling pathway
[108]
. Insulin also 
activates the intrinsic tyrosine kinase of insulin receptor, by phosphorylation of IRS-1. 
Both IGF-1 and IRS-1 are over-expressed in tumor cells, because they generate 
inhibition of apoptosis
109
. Furthermore, insulin resistance leads to release multiple pro-
inflammatory cytokines, including TNFα and IL-6, which promote the development of 
hepatic steatosis, inflammation and subsequent cancer within the liver
[110]
. Therefore, 
since insulin is a growth-promoting hormone with mitogen effects, exogenous insulin 
and sulphonylureas (which increase serum insulin levels) are considered to enhance 
carcinogenesis, while metformin that improves insulin sensitivity, decreased the risk of 
liver cancer development
[111]
. In fact, metformin use decreases the risk of hepatocellular 
carcinoma by several mechanisms including: a) phosphorylated AMPK suppresses the 
Akt/mTOR signaling pathway, inhibiting cell proliferation
[112]
; b) modulate the 
expression of cytokines, such as TNFα and oxidative stress[113]; c) antiproliferative and 
antineoplastic effects associated with inhibition of mTORC1, but the mechanisms are 
poorly understood. 
Antidiabetic therapy is being widely evaluated in HCC. Hassan et al. compared 
420 diabetic patients with 1,104 healthy controls (diabetes mellitus was related to HCC 
(OR 4.2)). They analyzed different treatments, showing metformin and TZD as 
protective agents (OR 0.3) and sulphonylureas (OR 7.1) and insulin therapy (OR 1.9) as 
negative factors
[114]
. Donadon et al. obtained similar results, assessing 610 patients with 
HCC, 618 cirrhotic patients without HCC and 1,696 healthy controls. Metformin was 
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shown as protective therapy (OR 0.33), opposite to sulphonylureas and insulin 
exogenous (OR 3.06)
[115]
. In other study, 19,349 diabetic patients were compared to 
77,396 healthy controls and demonstrated that the prevalence of HCC in diabetic 
patients was two times higher and that insulin sensitizers were protective (metformin 
OR 0.49: TZD OR 0.56)
[116]
. Similarly, Nkontchou et al. observed a reduced incidence 
of HCC in diabetic cirrhotic patients treated with metformin (HR 0.19)
[117]
.   
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Aims 
Primary aim 
-To assess the impact of type 2 diabetes mellitus on the development of hepatic 
encephalopathy and explore the mechanisms implicated. 
-To assess the role of insulin sensitizers on the development of overt hepatic 
encephalopathy. 
 
Secondary aim 
-To assess the role of diabetes mellitus on the diagnostic methods to detect minimal 
hepatic encephalopathy.  
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Summary of Results 
Several studies had shown a higher prevalence of HE in diabetic cirrhotic 
patients. Consequently, we aimed to find out the role of insulin sensitizers, particularly 
metformin, on the prevention of HE. For this purpose, we collected 82 cirrhotic patients 
with type 2 diabetes mellitus categorized according to metformin treatment; 41 of them 
were metformin-experienced (average time was 33.4±26.7 months) and 41 were non-
metformin-experienced (Figure 11). Both cohorts were similar in terms of gender 
distribution, age and liver function (including Child-Pugh score and MELD score). 
Etiology of cirrhosis was also similar, being alcohol-related cirrhosis the main etiology. 
Patients were analyzed according to HE risk score (defined by the presence of altered 
PHES, CFF and OGC, as well as genetic alterations). During the follow-up, hepatic 
encephalopathy was diagnosed in 23.2% (19/82) of overall cohort. Main HE triggers 
were diuretics (31.6%; 6/19) and variceal bleeding (26.2%; 5/19). There was a risk 
eight-times lower of having HE in patients on metformin treatment compared with non-
metformin-experienced patients (4.9% (2/41) vs 41.5% (17/41)) (logRank 9.81; p = 
0.002). In multivariate analysis, the metformin use was found independently associated 
with hepatic encephalopathy [H.R. 0.09 (95% CI: 0.01–0.83); p = 0.034], together with 
age at diagnosis [H.R. 1.12 (95% CI: 1.04–1.2); p = 0.002], female sex [H.R. 0.10 (95% 
CI: 0.01-0.67); p = 0.017] and HE risk [H.R. 21.3 (95% CI: 2.8–163.4); p = 0.003]. 
Additionally, metformin-experienced patients showed a trend to lower TNFr2 levels, 
compared to non-metformin treated patients, which could indicate the action on pro-
inflammatory cytokines. Furthermore, we found that HOMA index was independently 
associated with higher rate of overt HE in Child-Pugh A patients. This fact is 
interesting, because supporting the hypothesis that insulin resistance syndrome could 
promote inflammation and increased risk of overt HE. On the other hand, overall 
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survival rate reached a trend in metformin-experienced patients: 92.7% (38/41) vs 
82.9% (34/41) (p > 0.05). 
 
 
 
 
 
 
 
 
Figure 11. Distribution of patients in case-control study. 
 
On the other hand, we carried out an experimental study in vitro to find out the 
mechanism by metformin could prevent from HE. In the enzymatic assay, different 
metformin doses (from 0 to 100 mM) were tested with a constant glutamine 
concentration (100 mM) (Figure 12). We observed a dose-dependent reduction of the 
glutaminase activity with metformin use. Specifically, it was observed 17.5% of 
glutaminase activity inhibition with a metformin concentration of 10 mM, reaching up 
to 68% inhibition with higher doses.  
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Figure 12. Chemical assay. 
 
On the other hand, Caco2 cells were cultured in presence of different metformin 
doses (0, 20, 50, 100 and 200 mM) to perform the cells assay (Figure 13). Glutaminase 
activity showed a 24% of inhibition in Caco2 cells with 20 mM of metformin at 72 
hours, compared with the control at the same time. Furthermore, we observed a decrease 
in ammonia production from 26.85±0.74 mM to 19.9±2.05 mM (p=0.05). Other higher 
metformin concentrations inhibited also the glutaminase activity, but this effect was not 
different than 20 mM of metformin. 
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Figure 13. Cells assay. 
 
Additionally to published papers, we have submitted different studies to national 
and international congresses. One of them consisted in assessing if the presence of 
diabetes mellitus could alter the results of the different tests to diagnose MHE. Thus, we 
collected 133 cirrhotic patients, being 36.1% (48/133) diabetics. Liver function did not 
show any difference between diabetic and non-diabetic patients: a) MELD 9.65 vs 
10.35, p=0.357; b) Child-Pugh 6.13 vs 6.35, p=0.400. All cirrhotic patients were 
undergone to CFF, PHES and OGC as diagnostic tools to detect MHE. All tests 
detected MHE with similar percentages: 26.3% (35/95) with CFF, 28.6% (38/110) with 
PHES, and 32.3% (43/133) with OGC. In univariate analysis, diabetes mellitus was not 
associated with altered PHES (42.1% vs 30.6%; p=0.226) and OGC (37.5% vs 29.4%; 
p=0.338), but it was related to altered CFF (53.1% vs 28.6%; p=0.019). That is diabetes 
mellitus increased twice the risk of showing altered CFF. Adjusting by age, sex, MELD 
and TACC haplotype, the only variable associated independently with altered CFF was 
diabetes mellitus [O.R. 2.83 (95% CI: 1.17–6.86); p = 0.021].  
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Discussion 
The studies included in this thesis were designed to improve the knowledge and 
the daily clinical practice in the management of hepatic encephalopathy in cirrhotic 
patients. Results obtained in our studies allow us to make some general and specific 
recommendations about the impact of diabetes mellitus on hepatic encephalopathy, as 
well as the role of metformin on the prevention of this cirrhosis complication. 
 
How could diabetes mellitus promote overt HE? 
The prevalence of T2DM and insulin resistance is increasing in Western 
Countries due to the relationship with obesity and sedentary, so all medical conditions 
associated with them could be also increasing. Our results showed a closely relationship 
between T2DM and HE in cirrhotic patients, similar to the previous literature. Butt et al. 
prospectively enrolled 352 patients with decompensate cirrhosis to assess the impact of 
T2DM on the prevalence and severity of HE. According to West Haven criteria (it was 
the diagnostic scale for HE), 50.3% of patients presented HE. They observed that 58.5% 
of diabetic cirrhotic patients showed HE during the follow-up, while only the 42% of 
non-diabetic cirrhotic patients developed HE
[118]
. Similarly, Sigal et al. observed more 
frequency and more severity of HE in diabetic HCV-cirrhotic patients (in diabetics: 
35% mild, 60% severe; in non-diabetic patients: 58% mild, 20% severe) 
[119]
. Taking 
this special association into account, T2DM and insulin resistance could have a special 
relevance in the pathogenesis of HE (Figure 14). However, there are no studies about 
mechanisms explaining this association. 
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Firstly, diabetes mellitus seems to be able to modulate the glutaminase activity. 
Watford et al. carried out a study with rats which were made diabetic by injection of 
streptozotocin. They observed that diabetes mellitus caused: a) a slight increase in the 
glutaminase activity in the kidney; b) a 4-fold increase in hepatic glutaminase activity; 
c) an increase in the size of the small intestine; d) an increase in the glutaminase activity 
in the small intestine. When diabetes mellitus was prolonged, the small intestine was 
visibly enlarged and markedly increased in size (expressed as a percentage of body 
weight). In these long-term diabetic rats, the glutaminase activity of the small intestine 
was further increased
[120]
. As it has been explained above, the increase in the 
glutaminase activity leads to increase the ammonia production and, consequently, 
increase the risk of developing HE. 
Secondly, diabetes mellitus and insulin resistance are characterized by releasing 
pro-inflammatory cytokines, such as TNFα and IL-6, which increase the systemic 
inflammatory response
[121]
. The synergistic effect of ammonia and inflammation has 
been proposed, as there is a growing evidence showing the role of inflammation in 
exacerbating the symptoms of HE. The presence and severity of MHE in cirrhosis is 
independent of the severity of liver disease and plasma ammonia concentration; 
however, markers of inflammation are significantly higher in those with MHE 
compared to those without
[122]
. In a prospective study in patients showing HE grade 3/4 
as the primary indication for ICU admission, those with infection (but not ammonia) 
develop severe HE. Especially, SIRS score was significantly higher in patients with 
grade 4 than grade 3. These data highlight the importance of inflammation in severe HE, 
even without documented infection as 22% of these patients showing SIRS had no 
positive cultures identified
[123]
. Furthermore, Odeh et al. studied the relationship 
between serum levels of TNFα and HE, concluding that there was a positive correlation 
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with the severity of HE
[124]
. Similarly, serum levels of IL-6 were found higher in 
cirrhotic patients with MHE than those without MHE, and also a significant correlation 
with the severity of MHE was found
125
. During early stages of infection, TNFα is 
released. It increases the permeability of the blood-brain barrier and favors the diffusion 
of ammonia into the brain, resulting in HE
[126]
. Therefore, every pro-inflammatory 
condition (and diabetes mellitus is one of them) could increase the risk of developing 
HE. 
Thirdly, resistance to insulin actions could promote and increase the protein 
catabolism and, finally, ammonia production. This effect is consequence of insulin 
ability to stimulate protein synthesis, as well as inhibit protein degradation in peripheral 
tissues
[127]
. On the other hand, patients with liver cirrhosis and diabetes mellitus present 
malnutrition and often show reduced muscle mass, which could potentially influence on 
plasma ammonia levels and thereby possibly cognitive function. These findings suggest 
that low energy intake and poor nutritional status may facilitate the development of 
HE
[128]
. 
Lastly, diabetes mellitus is associated frequently with autonomic neuropathy. As 
a consequence of the complications in the digestive system, patients with diabetes 
mellitus may have specific gastrointestinal motility disorders, such as delayed 
duodenum-cecal transit time, gastroparesis and constipation. These effects can promote 
SIBO. Diabetes mellitus is implicated in impairments of enteric nervous system, which 
includes enteric neurons, interstitial cells of Cajal and neurotransmission pathways, as 
well as on oxidative stress, growth factors and gastrointestinal smooth muscle
[129]
. 
Therefore, delayed duodenum-cecal transit in diabetic patients is thought to cause SIBO 
in this population. In addition, autonomic neuropathy is common in patients with 
chronic liver disease. Maheswari et al. observed that cirrhotic patients with autonomic 
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neuropathy were more likely to develop HE due to prolonged intestinal transit time 
(90% compared to 67%; p = 0.02)
[130]
. 
 
 
 
 
 
 
 
 
 
 
Figure 14. Links between diabetes mellitus and hepatic encephalopathy. 
 
Impact of metformin on the developing of overt HE 
Given the fact that diabetes mellitus could increase the prevalence and severity 
of HE by reasons previously mentioned, we aimed to assess the role of insulin 
sensitizers (particularly, meftormin) to prevent HE. In our study, we included 
retrospectively 82 diabetic cirrhotic patients. Cases were defined as patients who were 
undergone to metformin treatment, while controls were defined as cirrhotic patients 
with T2DM without metformin treatment. We observed an eight-time lower risk of 
developing HE in patients on treatment with metformin compared with non-metformin-
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experienced patients, despite both cohorts were similar in terms of gender distribution, 
age, etiology of cirrhosis, liver function (including Child-Pugh score and MELD score) 
and HE risk score (defined according to altered CFF, PHES, OGC, as well as the 
presence of genetic alterations).  
Metformin is the first choice oral drug for T2DM. It decreases hyperglycemia 
primarily by suppressing the hepatic gluconeogenesis. In addition to suppressing hepatic 
glucose production, metformin increases insulin sensitivity, enhances peripheral glucose 
uptake, decreases insulin-induced suppression of fatty acid oxidation and decreases 
absorption of glucose from the gastrointestinal tract
[131]
. We hypothesized three possible 
mechanisms to explain, at least in part, the protective effect for HE in diabetic cirrhotic 
patients. First, we obtained a partial inhibition of glutaminase activity, both in the 
chemical and cells assays when compared with control experiments. To our knowledge, 
this is the first study to assess the influence of metformin on the glutaminase activity. 
This enzyme is the main source of ammonia production, so reducing its activity we can 
prevent from one of the most important triggers (hyperammoniagenic condition). 
Second, metformin seems to be able to modulate pro-inflammatory cytokines, which 
promote inflammation by activating macrophages and other immune cells. Metformin 
has been found to reduce the production of pro-inflammatory cytokines (IL-1β, IL-6, 
and TNFα) by inhibiting protein and mRNA expression in a dose-dependent 
manner
[132]
. Therefore, metformin acts on another clear trigger of HE, the systemic 
inflammatory response. Third, metformin seems to be able to modify the gut 
microbiota. In fact, metformin can profoundly affect the fecal microbial 
community. Metformin increases the number of goblet cells which causes an increase in 
Akkermansia, bacteria that use the mucus produced by the goblet cells as an energy 
source. Studies have shown that Akkermansia bacteria improve glucose tolerance and 
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decreases adipose tissue inflammation. In addition, its administration increases the 
intestinal levels of endocannabinoids, which has been demonstrated to control the 
inflammation
[133]
. 
The risks and benefits of metformin use in cirrhotic patients with diabetes 
mellitus are debated. When liver cirrhosis is diagnosed, physicians often discontinue 
metformin due to concerns about the risk of adverse effects in patients with liver 
dysfunction
[134]
. Main concern is metformin-associated metabolic acidosis, which has 
been largely represented by case reports
[135]
. However, metformin does not seem to 
cause or exacerbate liver injury and, indeed, is often beneficial in patients with 
NAFLD
[136]
, hepatitis C
[137]
 or hepatocellular carcinoma
[138]
. In a retrospective study, 
patients who continued treatment with metformin had a significantly longer median 
survival than those who discontinued the metformin use (11.8 vs. 5.6 years). 
Furthermore, the continuation of metformin after cirrhosis diagnosis reduced the risk of 
death by 57%
[139]
. Our results did not show any serious adverse effect, just some 
gastrointestinal symptoms such as diarrhea. In prospective studies, the prevalence of 
gastrointestinal symptoms (e.g. diarrhea) was around 30% of overall cohort
[140]
. 
Therefore, metformin could be safety continued in diabetic patients with cirrhosis if 
there is no specific contraindication. 
 
Impact of diabetes mellitus on the diagnose of MHE 
MHE is characterized by a variety of impairments only detected by 
psychometric or electrophysiological tests in patients with normal mental status
[141]
. To 
distinguish MHE from HE grade 1 is a challenge; thus, tests have been proposed to 
identify the impairment of mental function in patients with earlier stages of the HE 
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spectrum. These methods explore different pathways and mechanisms of disease, so 
they are complementary. The prevalence of MHE varies depending on the type of test 
and the threshold used to define it, being around one third of those with cirrhosis. Our 
results showed similar MHE detection rates: 26.3% with CFF, 28.6% with PHES, and 
32.3% with OGC. We aimed if diabetes mellitus could impact on these diagnostic 
methods. We found that 53.1% of diabetic cirrhotic patients showed altered CFF, while 
non-diabetics showed 28.6% (p=0.019). 
CFF has been growing in importance in the diagnosis of MHE and to distinguish 
different stages of the spectrum of HE, as reported in a recent meta-analysis
[142]
. CFF 
measures the ability of the central nervous system to detect flickering light. CFF has no 
contraindications, although we have to be careful in some situations such as patients 
with migraine (it has been reported to be significantly lower compared with healthy 
control individuals
[143]
). Similarly, CFF cannot be implemented in patients with visual 
defects. According to our results, cirrhotic patients having diabetes mellitus could show 
frequently an altered CFF. This fact could have several reasons. Firstly, diabetic patients 
often show visual defects, such as retinopathy
[144]
. In advanced stages, this entity is 
obvious and patients are not candidates to CFF. However, diabetic retinopathy could not 
be easily detected in earlier stages, influencing on the test. P100 wave latency, a type of 
visual evoked potential, has been found longer in diabetic patients as compared to 
normal controls, as well as there are a significant reduction in P100 amplitudes in 
diabetic subjects. Heravian et al. demonstrated that this impairment could be a sign of 
retinal ganglion cell damage, and could take place before the appearance of the first 
ophthalmoscopically detectable signs of diabetic retinopathy
[145]
. Secondly, diabetes 
mellitus is associated with different brain disorders. CFF assesses the cortical 
activity
[146]
, and diabetes mellitus has been related to cortical and subcortical infarctions 
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and, consequently, to mild cognitive impairment
[147]
. As such, the following 
mechanisms have been proposed: changes to brain vasculature, disturbances of cerebral 
insulin signaling, insulin resistance, glucose toxicity, oxidative stress, accumulation of 
advanced glycation end products and hypoglycemic episodes could be involved in this 
mild cognitive impairment
[148]
. In fact, diabetic patients with impaired cognition often 
show decreased spontaneous brain activity on resting-state functional magnetic 
resonance imaging
[149]
.  
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Conclusions 
1.- Type 2 diabetes mellitus could increase the incidence and the severity of hepatic 
encephalopathy. 
2.-Type 2 diabetes mellitus could promote hepatic encephalopathy by following 
mechanisms: 
 2.1.- Modulating the glutaminase activity. 
2.2.- Releasing pro-inflammatory cytokines, such as TNFα and IL-6, which 
increase the systemic inflammatory response. 
2.3.- Promoting and increasing the protein catabolism and, finally, the ammonia 
production. 
2.4.- Promoting delayed duodenum-cecal transit, by autonomic neuropathy, and 
consequently, causing small intestine bacterial overgrowth. 
3.- Metformin seems to prevent from overt hepatic encephalopathy by the following 
mechanisms: 
 3.1.- Inhibiting partially the glutaminase activity. 
 3.2.- Modulating the releasing of pro-inflammatory cytokines. 
4.- Metformin is able to modify the effect of diabetes mellitus on the hepatic 
encephalopathy, decreasing the risk of developing. 
5.- Metformin seems to be a safety drug in cirrhotic patients. 
6.- Diabetes mellitus could influence on the tests to detect minimal hepatic 
encephalopathy, especially on critical flicker frequency.  
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Anexo I 
Relación de las tablas incluidas en la tesis 
Table 1. Diagnostic methods for liver cirrhosis. 
Table 2. Classification of hepatic encephalopathy. 
Table 3. Regulation of hepatic glutaminase and glutamine synthetase. 
Table 4. Stages of hepatic encephalopathy. 
Table 5. Glasgow scale. 
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Anexo II 
Relación de las figuras incluidas en la tesis 
Figure 1. Spectrum of hepatic encephalopathy. 
Figure 2. Potential hyperammoniagenic conditions. 
Figure 3. Ammonia detoxification: glutamine cycling and ureagenesis. 
Figure 4. Pleomorphic effects of ammonia. 
Figure 5. Mechanisms and effects of ammonia uptake into the brain. 
Figure 6. Mechanisms of bacterial translocation from gastrointestinal tract. 
Figure 7. Glutaminase gene is located in chromosome 2. 
Figure 8. Psychometric hepatic encephalopathy score. 
Figure 9. Relevant aspects of the treatment of hepatic encephalopathy. 
Figure 10. Effects of insulin resistance. 
Figure 11. Distribution of patients in case-control study. 
Figure 12. Chemical assay. 
Figure 13. Cells assay. 
Figure 14. Links between diabetes mellitus and hepatic encephalopathy. 
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